overview

• Mark D. Mannie earned a BS degree from the University of Georgia and a PhD degree from Northwestern University. He then obtained a Post-Doctoral Fellowship from the National Multiple Sclerosis Society (NMSS) to continue research in neuroimmunology and CNS autoimmunity at the University of Michigan. Dr. Mannie then joined the Department of Microbiology and Immunology (BSOM) in July of 1990. Dr. Mannie has been extensively involved in teaching M1 students including service as a Course Director for Medical Microbiology and Immunology (1999-2013) and continuous service as the primary teacher for basic and clinical Immunology (2 months/ year) for the past 2 decades. Dr. Mannie was recognized as a Master Educator in 2013. Dr. Mannie leads a research lab that has been continuously funded over the past 3 decades from the National Multiple Sclerosis Society or the National Institutes of Health. His laboratory is currently funded by a R01 grant from the NIAID. Dr. Mannie has extensive service experience on grant review panels, including more than 45 study sections from the NIH, the NMSS, and the Department of Defense during the past 13 years. Dr. Mannie is currently the primary mentor for one PhD student and has graduated a total of 5 PhD students during the past 5 years. Dr. Mannie's laboratory invented a new class of vaccines that elicits immunological tolerance to prevent and reverse inflammatory autoimmune disease, with a focus on the neurodegenerative demyelinating disease Multiple Sclerosis. Dr. Mannie is the primary inventor of four patents/ patent portfolios that have been licensed by ECU. Three of these patents have been licensed to a biotechnology company (TregTherapeutics) whose primary mission is to advance these tolerogenic vaccines into early-stage clinical trials. Dr. Mannie recently initiated a new research program focusing on developing new therapeutics to treat COVID-19. Dr. Mannie has also significantly advanced novel technologies underlying cell-based adoptive immunotherapy for chronic inflammatory disease. Over the next ten years, the Mannie laboratory anticipates advancing novel technologies that will significantly impact inflammatory neurodegenerative diseases such as Multiple Sclerosis as well as advancing a new platform of anti-viral therapeutics.